Announced details
Cancer drug development and drug discovery research targeting transcriptional regulation in cancer cells
Our company led the research and generated the research results in collaboration with the research teams of Takeda Pharmaceutical Company Limited and Axcelead Drug Discovery Partners株式会社.
The research teams of Takeda Pharmaceutical Company Limited and Axcelead Drug Discovery Partners株式会社. ACS Medicinal Chemistry Letters is an international academic journal published by the American Chemical Society (ACS). Other information on locations, representatives, paid-in capital and year of establishment is Not disclosed.
Fujisawa, Kanagawa Prefecture (the company's head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
ACS Medicinal Chemistry Letters, the paper “Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug,” DOI: 10.1021/acsmedchemlett.6c00138
| Item | Details |
|---|---|
| Names of Products / Services Covered | CDK12 inhibitor CTX-439 |
| Counterparty | Takeda Pharmaceutical Company Limited, Axcelead Drug Discovery Partners株式会社, ACS Medicinal Chemistry Letters |
| Counterparty overview | The research teams of Takeda Pharmaceutical Company Limited and Axcelead Drug Discovery Partners株式会社. ACS Medicinal Chemistry Letters is an international academic journal published by the American Chemical Society (ACS). Other information on locations, representatives, paid-in capital and year of establishment is Not disclosed. |
| Relationship with the Company | Our company led the research and generated the research results in collaboration with the research teams of Takeda Pharmaceutical Company Limited and Axcelead Drug Discovery Partners株式会社. |
| Launch date | 23 June 2026 (paper published online, actual) |
| Applicable area | Cancer drug development and drug discovery research targeting transcriptional regulation in cancer cells |
| Location | Fujisawa, Kanagawa Prefecture (the company's head office) |
| Source | ACS Medicinal Chemistry Letters, the paper “Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug,” DOI: 10.1021/acsmedchemlett.6c00138 |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the research results that led to the discovery of CTX-439.